Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

Exclusion Criteria

• •Those at high risk for acute allograft rejection, including those who receive a second or more renal transplant, those with a history of panel reactive antibody levels \>20%, and those considered by investigators to be at relatively higher risk for acute rejection
• •Human leukocyte antigen-identical donor-recipient pairs
• •Cold ischemia time \>36 hours (donor kidney)
• •Participants who are positive for hepatitis C antibody, on polymerase chain reaction, for hepatitis B surface antigen, and for human immunodeficiency virus
• •A positive purified protein derivative tuberculosis test (test performed within 1 year of enrollment), unless previously vaccinated with Bacille-Calmette-Guérin or those who had a history of adequate chemoprophylaxis
• •Any active infection that would normally exclude transplantation
• •Recipients of multiple organ transplants
• •Donor age \>60 or \<6 years or donors whose hearts were not beating
• •Recipients with underlying renal disease of (due to risk of rapid disease recurrence in the allograft): focal segmental glomerulosclerosis, Type I or II membranoproliferative glomerulonephritis, or hemolytic uremic syndrome/ thrombotic thrombocytopenic purpura
• •A positive T-cell lymphocytoxic crossmatch using donor lymphocytes and recipient serum
• •A history of true allergy to intravenous iodinated roentgenographic contrast agents
• •Participants with life expectancy severely limited by disease state or other underlying medical condition
• •A history of cancer (other than nonmelanoma skin cell cancers cured by local resection) within the last 5 years
• •Mammogram film with any clinically significant abnormality requiring further investigation or biopsies
• •History of substance abuse (drug or alcohol) or psychotic disorders that were not compatible with adequate study follow-up
• •A currently functioning, nonrenal transplant
• •Previous treatment with basiliximab for any reason
• •Active peptic ulcer disease, chronic diarrhea, or gastrointestinal malabsorption
• •Those who had used any investigational drug within 30 days before the Day 1 visit.